Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Isolated Limb Perfusion of Melphalan for Melanoma and Sarcoma Treatment (ILI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01920516
Recruitment Status : Unknown
Verified February 2019 by Giammaria Fiorentini, International Group of Endovascular Oncology.
Recruitment status was:  Recruiting
First Posted : August 12, 2013
Last Update Posted : February 27, 2019
Sponsor:
Information provided by (Responsible Party):
Giammaria Fiorentini, International Group of Endovascular Oncology

Tracking Information
First Submitted Date August 6, 2013
First Posted Date August 12, 2013
Last Update Posted Date February 27, 2019
Study Start Date July 2013
Estimated Primary Completion Date June 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: April 16, 2015)
Tumor response [ Time Frame: 12 months ]
Response must be assessed by repeating the following examinations, at Day 30, Day 90 and Day 120 after start of treatment: Chest-abdomen CAT scan with and without contrast medium (refer to Section 4). Evaluation will be based on RECIST criteria [18-22 ] cancer markers (CEA, CA 19.9)
Original Primary Outcome Measures
 (submitted: August 8, 2013)
  • Tumor response [ Time Frame: 12 months ]
    Response must be assessed by repeating the following examinations, at Day 30, Day 90 and Day 120 after start of treatment: Chest-abdomen CAT scan with and without contrast medium (refer to Section 4). Evaluation will be based on RECIST criteria [18-22 ] cancer markers (CEA, CA 19.9)
  • progression free survival [ Time Frame: 12 months ]
Change History
Current Secondary Outcome Measures
 (submitted: February 26, 2019)
  • survival rate [ Time Frame: 12 months ]
    percentage of patients alive
  • time to progression [ Time Frame: 12 months ]
    time from treatment start to progression
  • number of adverse events [ Time Frame: 4 months ]
    number of adverse events
Original Secondary Outcome Measures
 (submitted: August 8, 2013)
  • survival rate [ Time Frame: 12 months ]
  • time to progression [ Time Frame: 12 months ]
  • number of adverse events [ Time Frame: 4 months ]
  • Quality of life [ Time Frame: 4 months ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Isolated Limb Perfusion of Melphalan for Melanoma and Sarcoma Treatment
Official Title Prospective Observational Study on Isolated Limb Perfusion of Melphalan in Treating Patients With Metastasis or Recidivism of Limb Melanoma or Sarcoma That Are Not Operable
Brief Summary

In-transit metastases occur in approximately 3% of melanoma patients, can be very symptomatic and the survival in this group may be prolonged. In-transit melanoma metastases are often confined to a limb. In this circumstance, treatment by isolated limb perfusion or isolated limb infusion can be a remarkably effective regional treatment option. Isolated limb infusion (ILI) was introduced in 1992 and is a technique used to deliver regional chemotherapy to treat advanced melanoma confined to a limb. Regional chemotherapy with melphalan delivered by isolated limb perfusion (ILP) or ILI are effective treatment options for in-transit melanoma and are generally well tolerated.

ILI is a less invasive and simpler alternative to ILP. Complete response rates are 45- 69% for ILP and 23-44% for ILI. The limb is often warmed to lower temperatures in ILI compared to ILP and the limb becomes progressively more hypoxic and acidotic during ILI, each of these parameters potentially having an effect on outcome. ILP & ILI are used primarily as palliative options when excision of in-transit metastases is unfeasible but can be used as an adjunctive procedure to surgery, for other tumour types such as merkel cell carcinoma, and can be repeated if indicated. For ILI correction of melphalan dose for ideal body weight has been shown to substantially decrease the rates of severe local toxicity while maintaining complete response rates, but overall response rate is reduced.

Response to ILI, moreover, is different in upper and lower limbs. ILI for Upper limbs disease is associated with similar complete response rates but lower toxicity than ILI for Lower limbs E disease and with different physiologic sequelae despite comparable methods. The Upper limbs appears relatively resistant to toxic effects of melphalan-based ILI as currently performed, which suggests a potential for further optimization of drug dosing for Upper limbs ILI.

Regional therapy is an excellent therapeutic modality for disease limited to a limb and furthermore serves as an excellent model for scientific investigation, both clinical and translational. In this study we want to collect data on isolated limb infusion of chemotherapy to monitor efficacy and tolerability in patients with melanoma metastases of the arm or leg that cannot be removed by surgery.

Detailed Description

This is an observational study and the treatment is related to the experiences and economical availability of each center.

Study Design: Prospective observational study . Primary objective: To collect data on tumor response and progression free survival after administration of melphalan.

Secondary objectives: To collect data on survival rate, time to progression, morbidity tolerability of treatment, number of treatment required to achieve objective response and improvement of quality of life (Edmonton questionnaire)

Treatment under observation :

Patients undergo fluoroscopic placement of angiographic arterial and venous catheters into the appropriate extremity in order to infuse the drug (artery) and to stop the out flow (venous with balloon catheter). Melphalan 1mg/kgr is rapidly infused into the isolated limb via the arterial catheter after the inflation of venous balloon catheter. Then the circulation of the limb is blocked with a pneumatic cuff at the root of the limb . Patients with little or no response at 8 weeks may receive up to 2 additional treatments at the discretion of the treating physician.

Patients are followed at 1-2 weeks, 3-4 weeks, 6-8 weeks, and then every 3-6 months thereafter as deemed necessary by the treating physician.

Day -1 Melphalan 1mg/ Kgr has been prepared at Pharmacy.

Day 0: prehydration, antibiotic prophylaxis and setting up of a therapeutic scheme appropriate for analgesic prophylaxis (3-day duration) as previously reported (25)

Day +1:

Upon admittance to the radiology room, 1 vial of tropisetron (diluted in 100ml of physiological solution) administered by slow drip.

During infusion of the Melphalan into the artery, 1 vial of morphine hydrochloride diluted in 100 ml i.v. to be repeated one hour after the procedure and if necessary also after 6 hours.

Tropisetron i.v. if needed. Intra-arterial premedication with 1 vial of verapamil diluted in 4 ml of normal saline solution followed by 4 ml of lidocaine.

Intra femoral infusion of Melphalan Second ILI treatment could be repeated at side effects recovery ( following oncologist ' s planning of cure).

Day +30: The above procedure is repeated.

Day +90: In case of response, a third administration following the above procedures will be repeated.

Evaluation of response:

Response must be assessed by repeating the following examinations at Day 30, Day 90 and Day 120 after start of treatment:

Limb-Chest-abdomen CAT scan with and without contrast medium (refer to Section 4). Evaluation will be based on Response Evaluation Criteria in Solid Tumors (RECIST ) criteria [20-24 ] cancer markers (CEA, cancer antigen (CA) 19.9)

Assessment of quality of life The Edmonton Symptom Assessment System (ESAS) is used to monitor health conditions and quality of life.

Assessment of quality of life is performed during the baseline visit and at Day 30, Day 60 and Day 120 from start of treatment.

Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population primary care clinic
Condition Metastatic Melanoma
Intervention Drug: Melphalan
Melphalan 1mg/kgr is rapidly infused into the isolated limb via the arterial catheter after the inflation of venous baloon catheter.
Other Name: Alkeran
Study Groups/Cohorts Melphalan

Day +1:

Intra femoral infusion of Melphalan at the dosage 1mg/ Kg

Intra femoral infusion of Melphalan Second ILI treatment can be repeated at side effects recovery ( following oncologist ' s planning of cure).

Day +30: The above procedure is repeated.

Day +90: In case of response, a third administration following the above procedures will be repeated.

Intervention: Drug: Melphalan
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Unknown status
Estimated Enrollment
 (submitted: August 8, 2013)
40
Original Estimated Enrollment Same as current
Estimated Study Completion Date July 2020
Estimated Primary Completion Date June 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  1. Histologically proven primary or recurrent, regional melanoma or soft tissue sarcoma that is not amenable to surgical resection
  2. Majority (greater than 95%) of disease must be distal to the apex of the femoral triangle in the lower limb and the deltoid insertion in the upper limb
  3. Bidimensionally measurable disease in the extremity
  4. Patients with disease beyond the limb are eligible if their extremity disease requires palliative treatment in the judgment of their physician
  5. Age: more than 18
  6. Karnofsky 70-100%
  7. Life expectancy: At least 6 months
  8. Hematopoietic: WBC at least 3,000/mm^3
  9. Renal: Creatinine less than 2.0 mg/dL
  10. At least 4 weeks since prior antitumor therapy and recovered
  11. At least 2 weeks since prior antibiotics

Exclusion Criteria:

  1. Signs or symptoms of vascular insufficiency (no history of claudication or other ischemic peripheral vascular disease)
  2. pregnant or nursing
  3. other concurrent serious illness
  4. severe diabetes
  5. prior extremity complications due to diabetes
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Italy
Removed Location Countries  
 
Administrative Information
NCT Number NCT01920516
Other Study ID Numbers ILI01
ILI100513 ( Other Identifier: IGEVO )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Giammaria Fiorentini, International Group of Endovascular Oncology
Study Sponsor International Group of Endovascular Oncology
Collaborators Not Provided
Investigators
Principal Investigator: Giammaria Fiorentini, MD International Group of Endovascular Oncology
PRS Account International Group of Endovascular Oncology
Verification Date February 2019